PRN: High Potency API /HPAPI Market to Reach $24 Billion by 2021: Driven by the Rapid Growth in the Oncology Drugs Market

31/ago/2017 13:15:12 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 3 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

High Potency API /HPAPI Market to Reach $24 Billion by 2021: Driven by the Rapid Growth in the Oncology Drugs Market

 
[31-August-2017]
 

DUBLIN, August, 31, 2017 /PRNewswire/ --

The "High Potency API /HPAPI Market - Global Forecast to 2021" report has been added to Research and Markets' offering.

Research and Markets Logo

The global active pharmaceutical ingredients market is expected to reach USD 24.09 Billion by 2021 from USD 16.02 Billion in 2016, growing at a CAGR of 8.5% from 2016 to 2021.

Market growth is driven by the rapid growth in the oncology drugs market, growing demand for antibody drug conjugates, increasing focus of pharmaceutical companies on HPAPIs, and advancements in HPAPI technologies. Furthermore emerging markets and emerging technologies have opened an array of opportunities for the growth of the high potency active pharmaceutical ingredients market. The market also offers lucrative growth opportunities for CMO and CDMOs. However, factors such as stringent regulatory requirements and requirement of large investments may restrain the growth of this market. The active pharmaceutical ingredients market is segmented on the basis type, type of manufacturer, type of synthesis, therapeutic application, and region.

Based on type, the market is segmented into innovative and generic HPAPIs. The innovative HPAPIs segment is expected to account for the largest share in 2016. The large share of this segment is attributed to the presence of large number of patent-protected innovative HPAPIs, their higher price as compared to generics, growing focus of major players on the development of novel high-potency products, and the growing demand for high-potency cancer therapeutics. The generic HPAPIs segment is expected to register the highest growth rate in the forecast period. The impending patent cliff, increasing healthcare costs, and government initiatives to encourage the adoption of generics are the major factors driving the growth of this market segment.

On the basis of type of manufacture, the HPAPIs market is categorized into two segments, captive manufacturer and merchant manufacturer. In 2016, the captive manufacturers segment is estimated to account for the largest share. The large share of this segment is attributed to the preference of innovative companies to maintain in-house manufacturing facilities for their economic benefits. The merchant manufacturers segment is expected to register the highest CAGR during the forecast period. The high growth rate of the merchant manufacturers segment is attributed to the growing trend of outsourcing manufacturing processes.

On the basis of type of synthesis, the HPAPIs market is segmented into synthetic HPAPIs and biotech HPAPIs. The synthetic HPAPIs segment is estimated to command the largest share in 2016. The increasing emergence of new molecules in the market, rising number of new product approvals, technological advancements in synthesis, and ease of production are driving the growth of the synthetic HPAPIs segment. The biotech HPAPIs segment is expected to grow at the highest CAGR during the forecast period. Advances in biotechnology, growing demand for antibody drug conjugates, growing demand due to their specificity in action, their similarity with the natural biological compounds, and significant growth in the demand for monoclonal antibodies are the major factors driving the growth of this market.

On the basis of therapeutic application, the HPAPIs market is further segmented into oncology, hormonal imbalance, glaucoma, and other therapeutic applications. The oncology segment is estimated to account for the largest share of the global HPAPIs market in 2016. The growing incidence and prevalence of cancer across the globe and the launch of new target therapies in addition to technological advancements in the oncology HPAPI-antibody conjugate technology are major factors contributing to the growth of this application segment.

Companies Mentioned

  • Abbvie Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • ELI Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 High Potency Active Pharmaceutical Ingredients Classification and Overview

7 High Potency Active Pharmaceutical Ingredients Market, By Type

8 High Potency Active Pharmaceutical Ingredients Market, By Type of Synthesis

9 High Potency Active Pharmaceutical Ingredients Market, By Type of Manufacturer

10 High Potency Active Pharmaceutical Ingredients Market, By Therapeutic Application

11 High Potency Active Pharmaceutical Ingredients Market, By Region

12 Competitive Landscape

13 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/nbbw7s/high_potency_api

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl